IMMUNIC, INC. Files 8-K Report
Ticker: IMUX · Form: 8-K · Filed: Sep 25, 2025 · CIK: 1280776
| Field | Detail |
|---|---|
| Company | Immunic, INC. (IMUX) |
| Form Type | 8-K |
| Filed Date | Sep 25, 2025 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k
TL;DR
IMMUNIC, INC. filed an 8-K, likely containing routine updates.
AI Summary
On September 25, 2025, IMMUNIC, INC. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific financial figures or significant business events were detailed in the provided excerpt.
Why It Matters
This filing indicates IMMUNIC, INC. is providing updates to the SEC, which could contain important information for investors regarding the company's status or financial health.
Risk Assessment
Risk Level: low — The provided excerpt is a standard SEC filing notification without specific material events or financial disclosures that would indicate immediate risk.
Key Players & Entities
- IMMUNIC, INC. (company) — Registrant
- September 25, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 1200 Avenue of the Americas, Suite 200 New York, NY 10036 (address) — Principal executive offices
- (332) 255-9818 (phone_number) — Registrant's telephone number
FAQ
What specific 'Other Events' are reported in this 8-K filing?
The provided excerpt does not detail the specific 'Other Events' covered in the 8-K filing.
What is the nature of the 'Financial Statements and Exhibits' mentioned?
The excerpt does not specify the content of the 'Financial Statements and Exhibits' included in the filing.
When was IMMUNIC, INC. incorporated?
IMMUNIC, INC. was incorporated in Delaware.
What is the principal executive office address for IMMUNIC, INC.?
The principal executive office is located at 1200 Avenue of the Americas, Suite 200, New York, NY 10036.
What is the filing date for this 8-K report?
The filing date, and the date of the earliest event reported, is September 25, 2025.
Filing Stats: 1,122 words · 4 min read · ~4 pages · Grade level 13.9 · Accepted 2025-09-25 07:01:02
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 IMUX The Nasdaq Stock Market LLC In
Filing Documents
- e664856_8k-immunic.htm (8-K) — 27KB
- e664856_ex99-1.htm (EX-99.1) — 37KB
- e664856_ex99-2.htm (EX-99.2) — 9KB
- image1.jpg (GRAPHIC) — 5KB
- slide1.jpg (GRAPHIC) — 119KB
- slide2.jpg (GRAPHIC) — 159KB
- slide3.jpg (GRAPHIC) — 168KB
- slide4.jpg (GRAPHIC) — 214KB
- slide5.jpg (GRAPHIC) — 205KB
- slide6.jpg (GRAPHIC) — 185KB
- slide7.jpg (GRAPHIC) — 186KB
- slide8.jpg (GRAPHIC) — 182KB
- slide9.jpg (GRAPHIC) — 198KB
- slide10.jpg (GRAPHIC) — 187KB
- slide11.jpg (GRAPHIC) — 151KB
- slide12.jpg (GRAPHIC) — 191KB
- slide13.jpg (GRAPHIC) — 235KB
- 0001193805-25-001357.txt ( ) — 3534KB
- imux-20250925.xsd (EX-101.SCH) — 3KB
- imux-20250925_lab.xml (EX-101.LAB) — 33KB
- imux-20250925_pre.xml (EX-101.PRE) — 22KB
- e664856_8k-immunic_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On September 25, 2025, Immunic, Inc. (the " Company " or " Immunic ") issued a press release (the " Press Release ") announcing the presentation of key vidofludimus calcium data in an oral and four poster presentations (collectively, the " Presentation "), at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held September 24-26, 2025 in Barcelona, Spain. On September 24, 2025, Immunic posted a corporate presentation on the Company's website including new data from the Phase 2 CALLIPER trial of vidofludimus calcium in progressive multiple sclerosis. The Press Release and Presentation are attached as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K, respectively, and are incorporated herein by reference. The information in Item 8.01 of this Current Report on Form 8-K and Exhibit 99.1 and Exhibit 99.2 attached hereto shall not be deemed "filed" for the purposes of Section 18 of the Securities Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth therein. Cautionary Note Regarding Forward-Looking Certain statements in this Current Report on Form 8-K, the Press Release and the Presentation are "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this Current Report on Form 8-K, the Presentation, and the Press Release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of manage
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. Exhibit Description 99.1 Press Release, dated September 25, 2025. 99.2 Presentation, dated September 24, 2025. 104 Cover Page Interactive Data File (formatted as Inline XBRL).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Dated: September 25, 2025 Immunic, Inc. By: /s/ Daniel Vitt Daniel Vitt Chief Executive Officer